Cellectar Biosciences, Inc. (CLRB)
2.40
-0.01
(-0.41%)
USD |
NASDAQ |
Sep 09, 12:39
Cellectar Biosciences PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| March 30, 2012 | 59910.24 |
| March 29, 2012 | 55681.28 |
| March 28, 2012 | 66253.67 |
| March 27, 2012 | 66253.67 |
| March 26, 2012 | 67663.33 |
| March 23, 2012 | 63434.37 |
| March 22, 2012 | 63434.37 |
| March 21, 2012 | 54976.45 |
| March 20, 2012 | 45813.71 |
| March 19, 2012 | 42289.58 |
| March 16, 2012 | 41584.75 |
| March 15, 2012 | 39470.27 |
| March 14, 2012 | 42289.58 |
| March 13, 2012 | 38765.45 |
| March 12, 2012 | 38765.45 |
| March 09, 2012 | 38765.45 |
| March 08, 2012 | 35241.32 |
| March 07, 2012 | 35241.32 |
| March 06, 2012 | 35241.32 |
| March 05, 2012 | 35241.32 |
| March 02, 2012 | 35241.32 |
| March 01, 2012 | 35241.32 |
| February 29, 2012 | 35241.32 |
| February 28, 2012 | 35241.32 |
| February 27, 2012 | 35241.32 |
| Date | Value |
|---|---|
| February 24, 2012 | 35241.32 |
| February 23, 2012 | 35241.32 |
| February 22, 2012 | 35241.32 |
| February 21, 2012 | 33126.84 |
| February 17, 2012 | 33126.84 |
| February 16, 2012 | 33126.84 |
| February 15, 2012 | 33126.84 |
| February 14, 2012 | 35241.32 |
| February 13, 2012 | 35241.32 |
| February 10, 2012 | 33126.84 |
| February 09, 2012 | 33126.84 |
| February 08, 2012 | 35241.32 |
| February 07, 2012 | 35241.32 |
| February 06, 2012 | 35241.32 |
| February 03, 2012 | 33831.66 |
| February 02, 2012 | 35241.32 |
| February 01, 2012 | 33831.66 |
| January 31, 2012 | 33831.66 |
| January 30, 2012 | 35241.32 |
| January 27, 2012 | 34536.49 |
| January 26, 2012 | 33126.84 |
| January 25, 2012 | 30307.53 |
| January 24, 2012 | 35241.32 |
| January 23, 2012 | 33831.66 |
| January 20, 2012 | 31717.18 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.186 |
| Alnylam Pharmaceuticals, Inc. | 7.320 |
| Anika Therapeutics, Inc. | 2.447 |
| Savara, Inc. | -- |
| Vericel Corp. | 6.561 |
PS Ratio Related Metrics
| Price to Book Value | 0.6630 |
| Price | 2.40 |
| Earnings Yield | -189.8% |
| Market Cap | 19.81M |